drugset

drugset / Trial / NCT02638766

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

NCT02638766 ↗

Phase 2 Completed 15 enrolled Spanish Group for Research in Sarcomas Bayer · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.

Timeline

Start: 2015-11
Primary completion: 2021-08-31
Completion: 2021-08-31

Publications

Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernandez-Jover D, Gutierrez A, Serrano C, Monteagudo M, Leton R, Robledo M, Moura DS, Martin-Ruiz M, Lopez-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023 Aug 9;22(1):127. doi: 10.1186/s12943-023-01832-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Regorafenib	Small molecule	160 mg	Oral

Indications